CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that the Company will present biomarker data from its ongoing Phase 2 clinical trial of SY-1425, an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist, in genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) at the European School of Haematology’s 4th International Conference on Acute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment taking place October 5-7 in Estoril, Portugal.
The presentation will describe Syros’ proprietary RARA and IRF8 biomarkers, including their prevalence in AML and MDS patients screened for enrollment in the Phase 2 clinical trial to date. The presentation will also include data correlating biomarker status with myeloid differentiation in cells taken from patients upon screening for the trial and then treated ex vivo with SY-1425.
Details on the presentations are as follows:
Date & Time: Friday, October 6, from 7:05 – 8:30 p.m. WEST (2:05 -3:30
p.m. EDT)
Presentation Title: Novel RARA Pathway Activation
Biomarkers in Study SY-1425-201 Define a New Subset of AML and MDS
Patients and Correlate with Myeloid Differentiation Following Ex Vivo
SY-1425 Treatment
Session Title: Molecular Therapeutics
Presenter:
Emmanuelle di Tomaso, Ph.D., Vice President, Translational Medicine,
Syros
Abstract Number: 8882
Location: Estoril Congress Centre
About Syros Pharmaceuticals
Syros Pharmaceuticals is
pioneering the understanding of the non-coding region of the genome to
advance a new wave of medicines that control expression of
disease-driving genes. Syros has built a proprietary platform that is
designed to systematically and efficiently analyze this unexploited
region of DNA in human disease tissue to identify and drug novel targets
linked to genomically defined patient populations. Because gene
expression is fundamental to the function of all cells, Syros’ gene
control platform has broad potential to create medicines that achieve
profound and durable benefit across a range of diseases. Syros is
currently focused on cancer and immune-mediated diseases and is
advancing a growing pipeline of gene control medicines. Syros’ lead drug
candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical
trial for genomically defined subsets of patients with acute myeloid
leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7
inhibitor in a Phase 1 clinical trial for patients with advanced solid
tumors, including transcriptionally dependent cancers such as triple
negative breast, small cell lung and ovarian cancers. Led by a team with
deep experience in drug discovery, development and commercialization,
Syros is located in Cambridge, Mass.
Cautionary Note Regarding Forward-Looking Statements
This
press release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995, including without
limitation statements regarding the therapeutic benefit of SY-1425 and
the benefits of Syros’ gene control platform. The words ‘‘anticipate,’’
‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’
‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’
‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended
to identify forward-looking statements, although not all forward-looking
statements contain these identifying words. Moreover, there can be no
assurance that data generated to date in the ongoing Phase 2 clinical
trial of SY-1425 are predictive of the ability of such trial to meet any
of its endpoints. Actual results or events could differ materially from
the plans, intentions and expectations disclosed in these
forward-looking statements as a result of various important factors,
including Syros’ ability to: advance the development of its programs,
including SY-1425 and SY-1365, under the timelines it projects in
current and future clinical trials; demonstrate in any current and
future clinical trials the requisite safety, efficacy and combinability
of its drug candidates; replicate scientific and non-clinical data in
clinical trials; successfully develop a companion diagnostic test to
identify patients with the RARA and IRF8 biomarkers; obtain and maintain
patent protection for its drug candidates and the freedom to operate
under third party intellectual property; obtain and maintain necessary
regulatory approvals; identify, enter into and maintain collaboration
agreements with third parties; manage competition; manage expenses;
raise the substantial additional capital needed to achieve its business
objectives; attract and retain qualified personnel; and successfully
execute on its business strategies; risks described under the caption
“Risk Factors” in Syros’ Quarterly Report on Form 10-Q for the quarter
ended June 30, 2017, which is on file with the Securities and Exchange
Commission; and risks described in other filings that Syros makes with
the Securities and Exchange Commission in the future. Any
forward-looking statements contained in this press release speak only as
of the date hereof, and Syros expressly disclaims any obligation to
update any forward-looking statements, whether because of new
information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170929005078/en/
Media Contact:
Syros Pharmaceuticals
Naomi Aoki,
617-283-4298
naoki@syros.com
or
Investor
Contact:
Stern Investor Relations, Inc.
Hannah
Deresiewicz, 212-362-1200
hannahd@sternir.com
Source: Syros Pharmaceuticals
Released September 29, 2017